A monthly pill would add to the growing number of choices for HIV preexposure prophylaxis, which is now seen as the best hope ...

At the IAS 2025 conference in Kigali, Rwanda, Banky Olatosi, M.P.H., M.S., Ph.D., of the University of South Carolina, shed ...

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

Mulugeta Gebregziabher, Ph.D., spoke with Managed Healthcare Executive ahead of his presentation at IAS 2025 in Kigali, Rwanda, about the risks posed by U.S. cuts to global HIV prevention funding.

A class of drugs, MDM2 inhibitors, being studied as cancer therapeutics may accidentally damage the protective barriers in the brain and eyes, finds new research in mice.

In this interview, Matthew Yarnell, president of SEIU Healthcare, Pennsylvania, a healthcare union, condemns Trump’s $1 ...

The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...

Integrating people-centered HIV care with primary health care is essential to improving access, equity and health outcomes, but doing so successfully requires coordinated policies, digital ...

While successes have been seen because of HIV self-testing, funding cuts to USAID and PEPFAR will make continued research difficult, according to Anna Bershteyn, Ph.D., associate professor in the ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

A separate analysis of the real-world trial found that those who switched from daily antiretroviral treatment to Cabenuva had fewer concerns about treatment.

According to experts at the IAS 2025 meeting in Kigali, Rwanda, AI revolutionizes HIV vaccine development by enhancing design ...